secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001493152-24-025382
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024
--------------------------------------------------------------------------------

- FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.
- Initial Phase 1 clinical data for GTB-3650 expected in H1 2025.
- GTB-5550 IND submission (B7H3 solid tumors) expected Q1 2025; basket trial in six solid tumor types planned for 2025.
- Company becomes fully remote effective July 1, 2024; stockholder communications to San Francisco address.
- Cash runway expected to fund operations into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224025382/0001493152-24-025382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224025382/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-025382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer